pharmaphorum18m
FDA starts review of Sanofi's MS hope tolebrutinib
The FDA review – which is due to be completed by 28th September – revolves around the results of the HERCULES trial which ...
Sanofi Agrees US Autoimmune Drug Deal for Up to $1.9 Billion
Sanofi is buying an immunology drug from Dren Bio, Inc. for up to $1.9 billion, in a deal it said will help it become a ...
Serbian Monitor3h
Serbian scientists sell drug for autoimmune diseases and cancer for $1.9 billion
Sanofi, one of the world’s largest pharmaceutical companies, has acquired the Serbian biopharmaceutical company Dren Bio for ...
Sanofi Strengthens Its Immune System-Focused Pipeline With Around $2 Billion Dren Bio Deal
Sanofi is set to acquire DR-0201 from Dren Bio for up to $1.9 billion, aiming to expand its autoimmune disease pipeline with ...
Zacks.com on MSN4d
Sanofi Inks $1.9B Deal With Dren Bio to Buy Autoimmune Disease Drug
Through the Dren Bio deal, SNY intends to expand its immunology pipeline and establish itself as a leading immunology company ...
Sanofi: Tolebrutinib regulatory submission accepted for priority review in the US for patients with multiple sclerosis
Tolebrutinib regulatory submission accepted for priority review in the US for patients with multiple sclerosis If approved, tolebrutinib would be the first and only brain-penetrant BTK inhibitor to ...
BioSpace4d
Sanofi Commits up to $1.9B for Dren Bio’s Bispecific Antibody for Autoimmune Disease
The deal is the latest in a series of Sanofi investments in its immunology portfolio. According to Sanfoi, DR-0201 can ...
KTLA10d
Sanofi adopts FDA-selected flu strains to ensure readiness for the 2025-26 flu season
BRIDGEWATER, N.J., March 14, 2025 /PRNewswire/ -- Sanofi announced today the immediate adoption of influenza strains selected by the US Food and Drug Administration (FDA) to advance the ...